Caribou Biosciences to Participate in Upcoming Investor Conferences
Press Releases

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadership will participate in the following event and investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference, New York, NY
    September 4, 2024
  • 2024 Wells Fargo Healthcare Conference, Boston, MA
    September 5, 2024

During these conferences, Caribou leadership will conduct one-on-one meetings with investors registered. For more information, visit the Events page on Caribou’s website.

About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

Related Articles
TheFlyCaribou Biosciences reports Q3 EPS (38c), consensus (45c)
Carrie WilliamsCaribou Biosciences, Inc. (CRBU) Q3 Earnings Cheat Sheet
TheFlyCaribou Biosciences awarded EUR 1.6 million from France 2030
Go Ad-Free with Our App